A detailed history of Cva Family Office, LLC transactions in Argenx Se stock. As of the latest transaction made, Cva Family Office, LLC holds 5 shares of ARGX stock, worth $3,035. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5
Previous 3 66.67%
Holding current value
$3,035
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

BUY
$434.22 - $551.9 $868 - $1,103
2 Added 66.67%
5 $2,000
Q2 2024

Jul 09, 2024

BUY
$356.01 - $451.55 $356 - $451
1 Added 50.0%
3 $1,000
Q1 2024

Apr 10, 2024

SELL
$356.95 - $413.29 $1,070 - $1,239
-3 Reduced 60.0%
2 $0
Q4 2023

Jan 16, 2024

BUY
$338.91 - $506.01 $1,694 - $2,530
5 New
5 $1,000
Q2 2023

Jul 10, 2023

BUY
$360.14 - $422.58 $1,080 - $1,267
3 New
3 $1,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $33.6B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Cva Family Office, LLC Portfolio

Follow Cva Family Office, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cva Family Office, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cva Family Office, LLC with notifications on news.